Shearman & Sterling advised the underwriters in connection with Y-mAbs Therapeutics, Inc.’s follow-on public offering of 5.1 million shares of common stock at a public offering price of $28.00 per share, resulting in aggregate gross proceeds to Y-mAbs of approximately $143.8 million. The offering consisted of 5.1 million shares sold by Y-mAbs, including 669,750 shares sold pursuant to the exercise in full of the option to purchase additional shares granted to the underwriters by Y-mAbs in connection with the offering.
Morgan Stanley, J.P. Morgan and BofA Securities acted as joint book-running managers for the offering and Wedbush PacGrow and H.C. Wainwright & Co. acted as co-managers.
Y-mAbs Therapeutics is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company has a broad and advanced product pipeline, including two pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.